MEC Plus

DDR and DNA-Repair Pathways and Targets
DDR and DNA-Repair Pathways and Targets
Mamta Parikh, MD, MS
 View Video
BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology
BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology
Tycel Phillips, MD
 View Video
Contemporary Management of Urothelial Cancer
Contemporary Management of Urothelial Cancer
Abhishek Tripathi, MD
 View Video
Renal Cell Cancer: Recent Advances
Renal Cell Cancer: Recent Advances
Suchi Gulati, MD, MS, FACP
 View Video
Castration Resistant Prostate Cancer: What is the optimal treatment?
Castration Resistant Prostate Cancer: What is the optimal treatment?
Sandy Srinivas, MD
 View Video
State of the Art: Hormone-sensitive Prostate Cancer
State of the Art: Hormone-sensitive Prostate Cancer
Sarmad Sadeghi, MD, PhD
 View Video
Lymphoma: State of the Art
Lymphoma: State of the Art
Alex Herrera, MD
 View Video
AML and MDS: Beyond 7+3
AML and MDS: Beyond 7+3
Kevin Kelly, MD, PhD
 View Video
The Future of Developmental Therapeutics in Oncology
The Future of Developmental Therapeutics in Oncology
Patricia Mucci LoRusso, DO, PhD
 View Video
Updates in Treatment of Early Stage and Locally Advanced NSCLC
Updates in Treatment of Early Stage and Locally Advanced NSCLC
Jorge Nieva, MD
 View Video
Advances in Small Cell Lung Cancer and Mesothelioma/Thymic Malignancies
Advances in Small Cell Lung Cancer and Mesothelioma/Thymic Malignancies
Jyoti Malhotra, MD, MPH
 View Video
Updates in Targeted Therapy for NSCLC
Updates in Targeted Therapy for NSCLC
Jonathan W. Riess, MD, MS
 View Video
Updates in Immunotherapy for Lung Cancer
Updates in Immunotherapy for Lung Cancer
Mykola Onyshchenko, MD, PhD
 View Video
Advances in Esophageal and Gastric Cancer
Advances in Esophageal and Gastric Cancer
Syma Iqbal, MD
 View Video
Colorectal Cancer: State of the Art
Colorectal Cancer: State of the Art
Heinz-Josef Lenz, MD, FACP
 View Video
Pancreatic and Hepatobiliary Cancer: Emerging Strategies
Pancreatic and Hepatobiliary Cancer: Emerging Strategies
Edward Kim, MD, PhD
 View Video
Management of Immune Related Adverse Events
Management of Immune Related Adverse Events
Mary I. Carroll, DNP, FNP-C, OCN
 View Video
Advances in Car-T Cells Development for Cancer Therapy
Advances in Car-T Cells Development for Cancer Therapy
Mohamed Abou-el-Enein, MD, PhD, MSPH
 View Video
Advances in Non-PD(L)1 Immunotherapies
Advances in Non-PD(L)1 Immunotherapies
Miguel Villalona-Calero
 View Video
Convergence of Liquid Biopsy and Precision Oncology in the Management of NSCLC
Convergence of Liquid Biopsy and Precision Oncology in the Management of NSCLC
David Gandara, MD & Jonathan W. Riess, MD, MS
 View Video
Translating Pre-Clinical Studies to NCI-CTEP Clinical Trials
Translating Pre-Clinical Studies to NCI-CTEP Clinical Trials
Steven D. Gore, MD
 View Video
Novel Trial Designs for Early Phase Clinical Trials: Beyond 3+3
Novel Trial Designs for Early Phase Clinical Trials: Beyond 3+3
Paul Frankel, PhD
 View Video
Project Optimus and Optimizing Dose and Schedule in Early Phase Clinical Trials
Project Optimus and Optimizing Dose and Schedule in Early Phase Clinical Trials
Jan H. Beumer, PhD, PharmD, PhD, DABT
 View Video
Novel Treatment for Unresectable Stage III NSCLC
Novel Treatment for Unresectable Stage III NSCLC
Edgardo S. Santos Castillero, MD, FACP
 View Video
Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates
Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates
Hope Rugo, MD, FASCO
 View Video
Management of Neurological Toxicities from Immunotherapy: Diagnosis, Assessement and Therapy
Management of Neurological Toxicities from Immunotherapy: Diagnosis, Assessement and Therapy
Sajeel Chowdhary, MD
 View Video
Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors
Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors
Robert E. Marx, DDS, FACS
 View Video
Optimal Treatment for Early Stage HER2 Positive Breast Cancer: Tailoring Treatment to Response
Optimal Treatment for Early Stage HER2 Positive Breast Cancer: Tailoring Treatment to Response
Virginia Borges, MD
 View Video
Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer
Sequencing Endocrine Therapy and Targeted Agents for the Treatment of Metastatic HR+/HER2- Breast Cancer
Neelima Vidula, MD
 View Video

Displaying 1,081 - 1,110 of 2,995